Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yeah. i don't take that board too seriously. this is the place for more intelligent posters and good information.
what other boards do you go on ?
Pinksheets.com classifies APCU as "Limited Information" which they interpret as the following:
Designed for companies with financial reporting problems, economic distress, or in bankruptcy to make the limited information they have publicly available. The Limited Information category also includes companies that may not be troubled, but are unwilling to meet Pink Sheets' Guidelines for Providing Adequate Current Information. Companies in this category have limited financial information not older than six months available on the Pink Sheets News Service or have made a filing on the SEC's EDGAR system in the previous six months.
if they can not afford to file the financials how long do you think they are going to be around?
they still have not filed their financials.
POSC has stated that the reason they did not announce the NYSE company at the NASDAQ marketsite on May 5 was because " both parties were exploring expanding the current relationship"
my opinion is that there was a deal signed and they were (and are) discussing a much bigger deal.
ALSO COV was in the process of completeing the sale of 37 radiopharmacies to Triad Isotopes. Most people belive that that was part of the hold up. That deal was closed and announced on June 1 2010.
The Triad deal and potential COV/POSC deal are both considered by most to be in the same field...radiopharmacueticals.
The ev3 deal is not related in any way. Except that it demonstrates COV's strategy to sell off lower margin pieces and aquire higher margin pieces.
u r welcome. i can't give away all my tricks!!!!
lol
The IBJ article talks about losses from a long time ago when there was different management. It DOES NOT mention that they have a major NYSE company on the verge of doing business with POSC. It also DOES NOT mention the recent sales data. So it was dates May 29 but they leave out key positive info.
Here is the full article from IBJ (Indiana Businesss Journal)
Positron has billion-dollar hopes for medical-imaging scanner
May 29, 2010
A maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better at losing money than making it.
A maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in sales and build a multimillion-dollar cyclotron facility in five years.
But history shows Positron Corp. has been far better at losing money than making it.
The company sells and services nuclear scanners and related equipment that help diagnose cardiac and cancer ailments. The company moved its headquarters from Houston as of February, employing eight people here and another 10 around the country.
The company was founded 27 years ago and has racked up a whopping $95 million in losses since then. The public company’s stock trades over the counter for about 12 cents a share. And its main competitors include behemoths such as General Electric, Siemens and Philips.
But company executives contend things are finally turning around for Positron. They think their new scanner, launched a year ago, will soon reach sales sufficient to generate demand for a cyclotron facility to make the radioactive material used in the scanner.
Positron wants to locate that facility in central Indiana, although it is also examining sites and seeking incentives in Ohio and Illinois. The cyclotron could cost $50 million to $80 million and employ 85 people.
“The stars are aligning for us,” said Chief Operating Officer John Zehner, who joined Positron after selling his company, Fishers-based Dose Shield, to Positron in 2008. “We see a pretty bright future.”
He expects cardiologists to shift to the technology in Positron’s new scanner, which is called positron emission tomography, or PET.
The technology has been out of favor with cardiologists and nuclear medicine technicians, who have gravitated for years to machines that use SPECT, or single photon emission computed tomography. But for 2010, the federal Medicare program gave PET a 24-percent boost in reimbursement while dealing SPECT, which already got a lower reimbursement, a 23-percent cut. Medicare now pays more than $1,432 for a PET test.
Medicare’s rates are hugely important because the program covers more Americans than any private health insurer. But even more important, private health insurers often set their reimbursement rates by giving a slight premium to whatever Medicare is paying.
Both PET and SPECT machines are large enough to surround a patient as he or she sits or lies down. The most common reason cardiologists use the machines is to see if blood is flowing normally to the heart or if there is artery blockage.
Also working in Positron’s favor is a sudden shortage of one of the radioactive materials used in SPECT scanners, a substance known as molybdenum. The shortage, which has sparked hearings in Congress, came about after reactors that make the substance were shut down in Canada and the Netherlands.
Positron’s PET scanners, instead, use rubidium as their radioactive material, meaning the molybdenum shortage does not affect them.
Last, Positron’s PET scanner, the Attrius, sells for less than $1 million—about half the price most doctors and hospitals pay for PET machines from GE, Siemens and Philips. That’s because those larger companies’ scanners are combination products that add a CT scanner to the PET scanner.
Zehner believes the combination product is best suited for taking images of patients with cancer. For cardiac patients, however, the movement of their beating heart often forces the PET/CT scanners to take multiple images to get an accurate picture.
More images means more radiation—an increasing concern among health officials as the use of nuclear imaging tests has surged in the past 15 years. Positron argues that by using a stand-alone PET scanner for cardiac patients, it will give clearer images with less radiation exposure.
“It’s a good argument,” said Bob Cimasi, president of St. Louis-based Health Capital Consultants, a business adviser to doctors and hospitals. “They’re a terrific company. And they’ve got a lot going for them with this technology.”
But, of course, there are many challenges, too, Cimasi said. Because there’s been such a surge in the use of imaging, Medicare and private health insurers are on a warpath to limit its use.
Some are requiring physicians to get authorization before doing an image test. Also, the recently passed health care reform bill stipulates that a physician or hospital that installs a diagnostic imaging machine must show enough patient demand to use the machine to at least 75 percent of its capacity.
“You don’t have to be a weatherman to know which way the wind is blowing,” Cimasi said. “There’s just this overall bias against diagnostic imaging.”
Positron’s focus on cardiologists is smart, Cimasi said, as the cancer market is dominated by the big companies. But the company will have to sell its machines at a time cardiology practices are consolidating rapidly, either with one another or with a hospital. That means fewer overall buyers—or at least fewer potential doors to knock on to get sales.
Dr. Kiran Kareti has been investigating PET scanners for Community Heart and Vascular in Indianapolis. The system currently has four or five SPECT scanners. But Kareti has noticed a few benefits to the PET technology.
PET scans can be done in about an hour, compared with about four hours for SPECT scans, Kareti said. And the PET scan can provide a clearer image, especially in today’s larger patients. Last, PET scans allow cardiologists to quantify the rate of blood flow, whereas SPECT scans allow for a qualitative assessment.
“To me it seems promising,” said Kareti, a cardiologist who is director of diagnostic testing at Community Heart and Vascular. He added, “I’ve been speaking with our administration about this—that, hopefully, this is something that we can use in the near future.”
Positron, however, has a name-recognition issue. Kareti has never heard of the company.
That may be why Positron has sold few PET scanners since its Attrius model won approval from the U.S. Food and Drug Administration in April 2009. Zehner declined to give the exact number of machines sold, but the company has said the number of customers getting quotes on its machines is 10 times last year’s.
Despite the new product, Positron’s overall sales actually declined in 2009, to $1.4 million, down from $2.1 million the year before. Its negative cash flow and losses worsened even though sales picked up in the first quarter this year.
Positron’s stock price has spiked this year, rising from 7 cents apiece at year end to as high as 26 cents April 21.•
indiana journal article on what specificly
COV is one of the largest healthcare companies in the world. Why do you think if they make an aquisition in sleep therapy, that thay can not make another one in different area? You are thinking with your own pockets and realy don't grasp how huge they are and how deep their pockets are.
in other words one has nothing to do with the other.
Since COV has completed the sale to Triad.... I am expecting that during or after the Annual SNM Conference in Utah (June 5-9)we will hear something about a partnership deal.
By the way here is a link to the conference for those who have not seeen it
http://interactive.snm.org/index.cfm?PageID=9182
So lets assume the NYSE is Covidien..... (FROM 20-May-10 11:53AM) am
In December of 2009 COV announcedthe sale of 37 radiopharmacies to Triad Isotopes.
here is the link:http://www.triadisotopes.com/press-relea...
I spoke to a director at Triad today (5/20) and he said they are expecting and planning on closing that transaction by the end of May.
Now read this and decide for yourself what comes next. Notice that the new deal was not transacted until the sale was closed
NEW YORK (AP) -- Covidien PLC said Monday it will buy brain monitoring technology company Aspect Medical Systems Inc. for about $210 million, in a move meant to broaden the drug and medical device maker's product portfolio.
Ireland-based Covidien will pay $12 per share for Norwood, Mass.-based Aspect, marking a 56 percent premium to Aspect's closing price of $7.67 Friday. The deal should close by the end of the year.
The buyout comes a week after Covidien completed the sale of its sleep diagnostics unit assets to Embla Systems for an undisclosed amount. The company said it made the sale as part of a shift to focus more on its higher-margin businesses. Covidien also laid off 70 people at a medical supplies plant in Norfolk, Neb. last week as part of a restructuring move. The plant makes syringes and blood-collection tubes and will have 360 employees when the layoffs are complete in April. Covidien has more than 41,000 employees worldwide
STEP #1>>>>CHECK
Today (6/1) COV referred several times to the April 21 guidance Here is a piece of that conference call
"We look to make continued progress in margins as we improve our product mix, deliver manufacturing cost reductions and leverage the investment spending over the last few years.
We will continue our portfolio management activities providing incremental investment to large fast-growing product lines, while pruning those businesses that do not fit our growth and margin profile.
In addition, we look to broaden our product offerings through acquisition or licensing agreements and to expand into adjacent categories as we have been doing in the past. We will use our strong cash flow to make the investments that should allow us to drive sales and profitable growth."
Triad Isotopes Closes Acquisition of Covidien’s U.S. Network of Mallinckrodt Radiopharmacies
Contact: Tikisha Hughes
Triad Isotopes, Inc.
Direct: 407-455-6746
Fax: 407-455-6732
thughes@triadisotopes.com
For Immediate Release:
Triad Isotopes Closes Acquisition of Covidien’s U.S. Network of Mallinckrodt Radiopharmacies
Orlando, Florida. June 1, 2010 – Triad Isotopes, Inc., headquartered in Orlando, Florida, announced
today that it closed the previously announced acquisition of the U.S. radiopharmacy network owned and
operated by Covidien, a leading global healthcare products company based in Dublin, Ireland. This
transaction continues Triad Isotopes’ aggressive growth and investment in the radiopharmaceutical
industry.
Under the terms of the agreement, Triad has acquired the 37 Mallinckrodt radiopharmacies located in the
United States, with net sales of approximately $180 million in fiscal 2009. With this acquisition, Triad
becomes the second largest radiopharmacy network in the United States with over $300 million in annual
revenue, strengthening a national footprint and adding facilities located in 24 of the top 30 metropolitan
areas in the United States.
“We are pleased to welcome the Mallinckrodt network of radiopharmacies and new team members to
Triad. This transaction is the next logical step in our evolution allowing us to better serve our customers
and build value for our shareholders while making a positive impact in the communities we serve,” said
Dom Meffe, President & CEO of Triad.
As a result of the transaction, within 12 months Triad will increase the size of its total staff, from
approximately 800 employees to over 1,000, including doubling the size of its downtown home office as
corporate support services are added to Orlando.
Triad Isotopes, Inc. owns and operates 63 radiopharmacies and 6 cyclotron facilities located nationwide.
A radiopharmacy, also known as a nuclear pharmacy, is a pharmacy that compounds and distributes
radiopharmaceuticals used primarily in imaging procedures for cardiac and cancer diagnosis. Cyclotrons
are utilized to produce FDG (Fluorodeoxyglucose), a short-lived positron-emitting isotope suitable for
PET (Positron Emission Tomography), an imaging technology that can be used to assess tissue
biochemistry.
The Triad business model provides customers flexible and creative solutions, choice of product through
an open formulary and quick decision making at the local level. The Triad team is our customers’ trusted
advisor by supporting their clinical and operational needs while living in and improving the communities
they serve. For more information, visit www.triadisotopes.com.
triad-closes-acquisition-covidien.pdf
or maybe because something will be announced!
Board members of POSC will be attentding the SNM conference June 5-9. It is one of the biggest conferences of the year. Society of Nuclear Medicine's annnual meeting. All of the major players....Covidein Cardinal Health, GE , Phillips etc. will be there.
http://interactive.snm.org/index.cfm?Pag...
it has been my understanding that usually it is a few sales people and a technical guy that attend and present. I am not aware of board memebers attending most of these conferences..........bodes well for shareholders.
have some faith
there were some days where the market was down triple digits and we stayed flat and even up a bit.
well in a day or 2 COV will complete the transaction of selling 39 radiopharmacies to Triad so maybe the pharm-assist is the solution to fill the loss.
Here is a glimpse of COV aquisition strategy
On May 26, 2010, Covidien plc (the “Company”) issued a press release announcing entry into a definitive agreement to sell its Specialty Chemicals business to an affiliate of New Mountain Capital, L.L.C. for a cash purchase price of $280 million.
The decision to divest Specialty Chemicals was made following a thorough evaluation of a number of strategic alternatives. The decision is consistent with Covidien’s strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses, where the Company has or can develop a global competitive advantage.
above quoted from the 8K filed on may 26th
the flollowing is IMO
step 1) sell radio pharnacies to Triad (should be closed by May 31
step 2) aquire or partner with a company with higher margin capability
(hopefully us)
Covidien (COV) Considered Strongest Stock In Medical Devices Sector; Senior Analyst Gives It Buy-Rating
.Companies:CR Bard Inc.Becton, Dickinson and CompanyCovidien plc.On Tuesday May 11, 2010, 3:54 pm EDT
67 WALL STREET, New York - May 11, 2010 - The Wall Street Transcript has recently published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This Special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Effects of Health Care Reform - Increased Consolidation Through Mergers & Acquisitions - Repercussions of 2010 Medical Device Tax - Pricing Pressure from Hospitals - Orthopedic & Spine Companies as Beneficiaries of Health Care Reform - FDA Approval Process
Companies include: Vycor Medical (VYCO); ATS Medical (ATSI); Abbott Laboratories (ABT); Abiomed (ABMD); Accuray (ARAY); Allergan (AGN); American Medical Systems (AMMD); AngioDynamics (ANGO); ArthroCare (ARTC); Baxter (BAX); Bio-Rad Laboratiores (BIO); and many more.
In the following brief excerpt from the Medical Devices Special Report, expert analysts discuss the outlook for the sector and for investors.
Joanne K. Wuensch is a Research Analyst in the equity research group of BMO Capital Markets Corp., where she covers medical technology companies in the cardiology, ophthalmology, orthopedic and respiratory sectors. Her career in financial services began at JPMorgan, where, among other positions, she was an Associate in municipal finance investment banking in the health care and higher education group. Ms. Wuensch joined BMO Capital Markets in 2002. She holds an MPA from New York University and a B.A. from the University of Delaware.
TWST: What are the major trends in the medical devices industry at the moment?
Ms. Wuensch: There are several. Over the last year the focus for many investors has been health care reform, and while that is largely behind us, there are lingering questions. In addition, pricing, industry consolidation, new product pipelines and potential market share shifts are ongoing trends.
TWST: Which of these will have the most impact? Do you think it will be health care reform, consolidation or something else?
Ms. Wuensch: For the stocks, it is probably consolidation. For the industry, I could argue that both health care reform and consolidation over the next several years will be impactful. The good news is that we know that it is a 2.3% excise tax that will begin impacting the medical technology companies in 2013. With this knowledge, I think it is easier for organizations to value potential acquisitions and plan for the future. In 2009 there were 23 M And A transactions above $68 million, with only two above $1 billion. This compares to 2007, when there were 40 transactions, with 12 above $1 billion. Looking over the next 12 months to 18 months, we believe that the industry is prime for consolidation.
TWST: What stocks will benefit the most over the next several years? Which are in good shape to take advantage of the sway of the tide at the moment?
Ms. Wuensch: There are several ways to answer this. On a fundamental basis, we anticipate that hospital supply companies Covidien (COV), C.R. Bard (BCR) will benefit from the increased patient flow starting in 2014. From a consolidator point of view, companies such as Medtronic (MDT), Johnson And Johnson (JNJ), Abbott Laboratories (ABT), Covidien, Stryker (SYK), Zimmer (ZMH) and St. Jude Medical (STJ) have a fair amount of cash on their balance sheet and could benefit from purchasing faster-growing technologies. Finally, the smaller companies and their stocks could benefit. From my list, I've got a long list of possible acquirees. Some of this has already begun. In the last 12 months to 18 months, Covidien purchased VNUS Medical; Medtronic purchased Invatec and CoreValve; and Abbott purchased Advanced Medical Optics. But we believe that with health care reform well understood, large-cap multiples recovering and cash on the balance sheet, there will be more sooner rather than later.
TWST: What are the strongest stocks now?
Ms. Wuensch: Strongest in what way?
TWST: The best stock picks.
Ms. Wuensch: I think that Covidien is in a great position. The company, which has been publicly traded since June 2007, has been executing its strategic plan. Management has sold off noncore, lower-margin businesses, purchased adjacent, higher-margin businesses, and invested in research and development to drive higher operating margins. In addition, management has managed the company's debt burden, tax rate and cash flow. For the stock to work, continued leverage of the P And L, which should drive top-line growth and bottom-line returns, should do the trick. Stryker is another one. The stock should benefit from a recovering orthopaedic market, a recovering hospital purchasing environment - the MedSurg business is roughly 40% of sales - and an easing regulatory environment. Two of the company's four FDA warning letters have been lifted. Further, the company has almost $4 billion in cash on the balance sheet. Finally, I would point to NuVasive (NUVA). With reimbursement questions behind it, the company management has guided to 30% to 35% revenue growth in 2010, as it continues its momentum in the U.S. with the introduction of lateral access spine surgery. And management is just beginning to push outside of the United States. Further, the technology is well positioned in the current health care economic environment, as the procedure lowers operating room time, the number of hospital days and returns patients to their normal activities faster.
TWST: How is the economy affecting the industry at the moment?
Ms. Wuensch: At the moment, the industry is in a recovery mode. At the first light of the economic downturn, we witnessed a slowdown in breast augmentations, lap-band procedures and laser vision correction - things that are truly elective. The secondary items were items that are not so elective but can be considered elective for now, such as hips and knee procedures. During a very brief period, items that we never thought of as elective were impacted, items such as glaucoma eye drops. In the recovery mode, we are beginning to see a return of the hip and knee procedures but have not returned quite yet to the truly elective procedures, such as laser vision correction.
The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This Special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .
The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.
For Information on subscribing to The Wall Street Transcript, please call 800/246-7673
10Q reflecting orders above $3,000,000
Customer deposits of $1,065,000 include 2 Attrius? systems and 5 Nuclear Pharm-Assist?. This equals to orders above $3,000,000 based on a 30% down payment (not including orders without deposits).
This is 2 1/2 times of the yearly 2009 revenues. Considering that Positron received the radioactive materials license beginning of March 2010, i am very optimistic for the future.
IMO Positron is well on its projected targets.
copied from yahoo message board post @
21-May-10 09:15 am
I spoke to M Griffiths at Triad Isotopes yesterday (5/26) and he reiterated that they expect the trasnaction with COV to be completed by the end of May. So keep your eye out for a release any day now.
Think of the power and financial capability of COV marketing the Pharm-Assist. We will see unreal sales,revenue and POSC will be caught up in the flow, or bought up first!!!!!!!!!!!!!!!
yes of course. or you can email me at rick2424sev@yahoo.com
i dont think i can send private pms here.
if any major shareholder sold shares. a) they have to file a 144 form. b) they are restriceted to how many shares they can sell in any given month. do your homework next time before you embarras yourself with ignorant posts.
i dont expect any revenue from the new partnership this quarter. probably next quarter. i am hoping to see some new sales data.
no. i don't doubt it. but is not released yet so i don't want to say i know it is.......even though i do know.
Once the deal in anounced i think the story of POSC and the Pharm-Assist will gain mmomentum and attract other major companies to partner or buy POSC
So lets assume the NYSE partner is Covidien.......
In December of 2009 COV announced the sale of 37 radiopharmacies to Triad Isotopes.
here is the link: http://www.triadisotopes.com/press-release/2009/12-17-09.shtml
I spoke to a director at Triad today (5/20) and he said they are expecting and planning on closing that transaction by the end of May.
Now read this and decide for yourself what comes next. Notice that the new deal was not transacted until the sale was closed.
NEW YORK (AP) 9/28/2009 -- Covidien PLC said Monday it will buy brain monitoring technology company Aspect Medical Systems Inc. for about $210 million, in a move meant to broaden the drug and medical device maker's product portfolio.
Ireland-based Covidien will pay $12 per share for Norwood, Mass.-based Aspect, marking a 56 percent premium to Aspect's closing price of $7.67 Friday. The deal should close by the end of the year.
The buyout comes a week after Covidien completed the sale of its sleep diagnostics unit assets to Embla Systems for an undisclosed amount. The company said it made the sale as part of a shift to focus more on its higher-margin businesses. Covidien also laid off 70 people at a medical supplies plant in Norfolk, Neb. last week as part of a restructuring move. The plant makes syringes and blood-collection tubes and will have 360 employees when the layoffs are complete in April. Covidien has more than 41,000 employees worldwide
In the penny stock market...no news is bad news..........people give up and move on to other stocks when they don't get communication fron the company on a regular basis. hopefully we hear SOMETHING soon.
imo
POSC to present at trade show June 5-9
SNM
Society of Nuclear Medicine
http://www.snm.org
June 5-9, 2010 Salt Lake City, UT
Salt Palace Convention Center
Booth #1436
New article on POSC from biomed reports.com (READ HERE)
POSC: Damned if you do and damned if you don't
Written by Peter DePalma
Friday, 14 May 2010 05:47
After alerting members to Positron Corporation (OTC:POSC), the stock roared from $.06 to a fifty-two week high of $.30. Shortly after that, we advised our readers and subscribers that they should sell their positions in POSC before their scheduled press conference fearing that the event would become a "buy on rumor sell on news" event.
We've come back from vacation to an email box full of both love and hate mail, thus the title of today's article.
Apparently, our advice to "sell" prior to the press event did not go over well with many of the longs who felt that we were sending mixed messages about the stock, but after carefully considering what many day traders do with these "forward looking" types of stock plays, my editors felt strongly that we should advise our readers despite the back lash and they did.
As it turned out, things got even uglier than any of us expected when the penny stock company decided not to announce their highly anticipated partnership details to an audience of reporters in New York's Nasdaq Marketsite. Most of the reporters covering the event didn't even blink, but the tens of thousands of investors who were following the conference vis webcast immediately responded with a huge share dump. That resulted in the next wave of attacks and false accusations about promoting and/or pumping and dumping the pick. In the end, those of us who followed our own advice and erred on the side of caution won big while those who decided to gamble more speculatively than others paid an ugly price.
At the end of the day, the facts remain: POSC is a solid company that has been around for over 27 years. The CEO may need more media relations training given his very rough delivery at the podium, but reporters at the event (none of whom even asked about the partnership details that investors were craving) seemed to take the most interest in management's announcement that POSC anticipates generating over $200 million in revenue within 18 months and over a billion in revenue within 4 to 5 years. This is a stock that many of us have jumped back in on and is still available for mere pennies per share.
Eventhough they fully intended to when they news conference was scheduled, POSC could not announce the name of the key partnership they wanted to reveal at the press conference for a number of reasons. As we understand it, at least one contractual one and several strategic. As many disapointed and angry investors called and cried for full disclosure under threats of lawsuits, the company followed up with a cryptic press release about the matter in the days following the conference and although no one at the company can go on record publicly about it for the same reasons we mentioned, we have confirmed to the best of our abilities and based on candid interviews multiple sources, that they have partnered Covidien (NYSE:COV) and that they are also in the process of aligning with other big board companies for some very important strategic partnerships on the pharmaceutical side of the business. Furthermore, it's worth considering that any one of these strategic partners may chose to take over or buy the company; especially once the new network of automated imaging drug dispensing machines is set up.
At one point, one of Positron's newest allies had apparently even "threatened them" before deciding that joining forces might be a better way to respond to their innovative nuclear medicine's dispensing and distribution technology. The bonding experience with that company is still shaky, but much more friendly now according to those familiar with the situaiton and it definitely played into why the company decided against the public revelations.
If one looks at POSC and it's FDA approved PET Scan imaging technologies, the back orders for systems, and the shifts not only in the marketplace, but also the reimbursement as well as medical and technical needs of the cardio and oncology imaging space, it's clear to see that the company is not only undervalued, but vastly undervalued. Look up IMGG and you'll find a company that traded at close to $2 per share this year based on only "half the promise" that POSC offers today. That company has submitted for FDA approvals several times and still have no clearance, yet they still trade today at nearly fifty cents per share.
Is the company trading higher than it was when we first covered it? Absolutely and it is difficult to argue that the share price will not continue to rise as future revenues, orders and developments are announced. Do we continue to see it as a multi-bagger? Of course we do. Especially given the fact that the entire space they deal in is changing and that they are positioned without a single competitor as the leading company within that space.
Disclosure: Long POSC
POSC will be at this trade show June 5-8 http://www.snm.org/
uh ok so we don't want to hear about sales or revenue or trade shows or new hiring?
pretty stupid
we need some news outside of the partnership to keep momentum
we're looking at $200 million and the next five years $1 billion in revenue.
there it is in black and white from an 8K
Most important dialogue from the May 5 conference
UNIDENTIFIED PARTICIPANT: Just in terms of your revenue projections you said you're at $200 million now and expect to be up to $5 billion in so – I forget what time frame. How much is that going to be organic growth and how much is going to be dependent upon M&A or joint ventures?
ROONEY: Well, that's a good question. No, in fact over the next three years we're looking at $200 million and the next five years $1 billion in revenue. A majority of those numbers are from organic growth, yet our acceleration will be pretty significant in the next, next 18 months as we will know the extent of our certain strategic alliances and partners that we're working. These relationships will definitely assist us on a radiopharmaceutical side that advances us significantly.
Radiopharmaceuticals could really be a – will be a game changer and certain other radiopharmaceuticals that we're dealing with now could really expand that number even greater. I mean we're in this for the long haul, obviously – even longer than five years.
Here is the FULL TRANSCRIPT from the May 5 confernce (from the 8K)
POSITRON TRANSCRIPTION/Munc Media
May 7, 2010
8:20 am CT
PATRICK ROONEY, CHAIRMAN AND CEO, POSITRON CORPORATION: Well, thanks for that round of applause. We'd like to thank the NASDAQ for giving us the opportunity to introduce Positron Corporation. My name is Patrick Rooney. I am the Chairman and CEO of Positron.
With me are Joe Oliverio, Chief Technical Officer and Director of PET. Joe is one of the original partners that guided the further development of our technology and the company since 2006 when new management came into Positron.
To my right is John Zehner. John is the Director of Pharmaceuticals. John joined the company through Positron's acquisition of his company Dose Shield in 2008. John and his team have developed our proprietary automated dose dispensing technology and brings to Positron the nuclear pharmacy expertise that will immediately guide the company into the radiopharmaceutical space.
Positron is a molecular imaging company that specializes in nuclear cardiology. The company operates through two segments, molecular imaging devices and radiopharmaceuticals. In 2006, this new management team has taken an existing R&D technology company, refocus on the core competencies, advanced our PET technologies, made a number of strategic alliances and acquisitions that has transformed Positron into a true business enterprise and one we believe we are the future of the industry.
Right now I'm going to introduce again, Joe Oliverio so he can address our PET segment and after that, John Zehner will address the pharmaceutical segment. Thanks.
JOE OLIVERIO, CHIEF TECHNICAL OFFICER AND DIRECTOR OF PET, POSITRON CORPORATION: Thank you, Pat. Well, Positron has been manufacturing cardiac PET devices since 1983 under the guidance of world-renowned cardiologist K. Lance Gould. Dr. Gould has shaped our technology from both software and the hardware perspective, and we have an exclusive license for his intellectual property through the University of Texas moving forward.
We've sold devices to world-renowned institutions such as Yale, Beth Israel Medical Center, Madrid and University of Texas. In 2006 when the new management team came in, we set out to form a joint venture with a company that could excel our ideas. We formed a joint venture with Neusoft Medical Systems in Shenyang, China. What that gave us was an immediate decrease in manufacturing costs, a much larger capacity for manufacturing and also a strong engineering team that can deliver all of the improvements that we felt would position us for the market moving forward.
Our newly developed Pet scanner, the Attrius was FDA approved in May of 2009 and it's been about 12 months since then. There have been a lot of market dynamic changes, so you ask yourself why all of a sudden is our technology in high demand?
--------------------------------------------------------------------------------
Some of the market dynamic changes that I'll speak of are primarily due to the molybdenum shortage that is occurring world-wide. There are 7 million procedures performed annually using SPECT technology. Physicians are short of this key radiopharmaceutical which is resulting the cancelling of imaging patients.
Cardiac PET imaging with our scanner does not use molybdenum. The key radiopharmaceutical used in cardiac PET imaging is rubidium 82 which does not come from those sources where there are shortages. So that's a non-issue for PET.
The second reason is radiation exposure. The government is taking a very close look at cumulative radiation exposure for patients. The procedure cardiac PET is the lowest radiation exposure of any test that can be performed for the assessment of myocardial infusion.
In addition to that, Obama care is ideal for our product. Our researcher has shown through peer review literature that when switching from SPECT to PET technology, there's a 27 percent reduction in health care costs and a 50 percent reduction in angiograms and bypass surgeries. So Positron’s technology is much more cost-effective and appropriate for today's health care environment.
Additionally, and the most significant driving force, is reimbursement. As I've mentioned, there are 7 million SPECT procedures done annually on patients. The physicians in 2010 have experienced a drop of 30 percent in their reimbursement while PET has been increased by 20 percent. So now there is a very significant financial advantage for physicians – or incentives – for them to switch from SPECT to PET and that's a major driving force.
It should be noted that we're the only dedicated cardiac optimized PET scanner available in the market without the need for PET/CT. The only one in the world. The target market that we're looking at is facilities that have more than one SPECT camera where they perform at least 10 SPECT procedures per day.
Our market research shows that there are 3,000 cardiology groups with this opportunity in addition to 4,000 hospitals. So we have quite a significant opportunity to capture this market share, being the only dedicated cardiac PET scanner.
We intend to rapidly expand our sales and marketing efforts to be able to furnish this supply to this increased demand. There are other companies also that will help push this demand. Lantheus Corporation currently is developing a cardiac PET drug. They're in Phase II clinical trials at the FDA. Information can be found at clinicaltrial.gov under the key word Lantheus.
They have a case study to fall back on. They developed the SPECT radiopharmaceutical that I initially spoke about in 1982. Procedural volumes of SPECT back then were 1,000 to 2,000 and John can also speak to that as a radiopharmacist.
Lantheus took SPECT imaging from 1,000 to 2,000 to 7 million procedures done currently per year. They have divested their interest from SPECT and are investing in cardiac PET specifically, a cardiac PET drug that performs well on our scanner. So we expect not only Positron as a driving force but Lantheus as well. This multi-billion dollar corporation pushing cardiac PET and that will certainly only benefit Positron Corporation.
--------------------------------------------------------------------------------
That's all I have for now. And John Zehner will now speak to our radiopharmaceutical segment.
JOHN ZEHNER, DIRECTOR OF PHARMACEUTICALS, POSITRON CORPORATION: Thanks, Joe. Thanks, Pat. I represent the pharmacy side of Positron and as you've heard Joe talk about we have several exciting things going on in imaging. Everything in nuclear medicine requires some type of pharmaceutical to be able to do the image on the device.
So what I'm here to do is just give a brief overview of where we stand with our pharmaceutical products. What we have is a product line that automates the preparation and injection of the pharmaceuticals to patients. It kind of acts like a vending machine – and is able to prepare all the different types of pharmaceuticals that are used in imaging.
We currently have a focus on PET, but I want to be very opportunistic in SPECT. Our technology has several opportunities asJoe alluded to with the F 18 products from Lantheus going forward. So we feel that we have a lot of things addressed into the future.
The assist line – as we call it, allows our customers to interrupt the existing supply chain. What I mean by that is that it allows each customer to pick advantages that they currently would not have when they use our products. So if you look to a hospital, they can change how they image by going forward with different strategies on timing of their patient imaging.
With the nuclear pharmacies, they are allowed to change their distribution patterns, they can save costs with labor, and with manufacturers as it opens a wide variety of customer opportunities and different outlets. Our market represents the entire 7,000 opportunities that Joe discussed earlier, and we also have several more opportunities world-wide. Thanks.
ROONEY: Thank you. Well in closing, Positron's strategy is to utilize all of our innovative equipment to penetrate the molecular imaging market in a way that has never been done before.
Positron has the right management with the necessary expertise to meet our objectives. Positron's currently working with a number of strategic alliances that mutually benefit all parties in our expanding businesses.
Positron has an agreement with an industry-leading strategic partner. Positron has agreed with this partner that due to a recent expansion of the relationship and competitive advantages that it is in the best interest of all parties not to disclose any further details at this time. We'll do so in the very near future.
Based on market research and unique positioning in the marketplace, Positron’s targeted revenue projections are approximately $200 million over the next three years and an excess of $1 billion in the next five years. These sales numbers reflect Positron's PET devices and radiopharmaceutical sales and includes accelerated growth that will come from strategic partners.
--------------------------------------------------------------------------------
Positron has the potential for even greater growth as it expands into new markets with the broader indications that we will expect to be fully supported by Medicare and private payers. In our time here we've discussed all aspects of the company that we are at liberty to discuss. I believe that we have demonstrated some of the core value of Positron. We have shown how we are in an ideal position to be a leader in the molecular imaging industry. Please continue to follow our news releases for further information. Thank you. Please feel free to ask any questions you like.
UNIDENTIFIED PARTICIPANT: I have a quick question as it relates to your business and going forward. Do you guys plan on doing any future financings or are you looking for any capital to raise?
ROONEY: Sure. Actually at this time, we are well-capitalized. In the future with some of these expansion plans that are in the works, if you will, we will possibly be looking for – other capital. But this will happen, quite frankly, down the road as we expand with certain alliances in the future.
UNIDENTIFIED PARTICIPANT: And another question's related to the PET space and why you've actually dedicated your efforts in that space now instead of the PET/CT area.
ROONEY: Yes, you know what – I'm going to let Joe take that one.
OLIVERIO: Yes, I can answer that. PET/CT devices are very expensive. We have a significantly less expensive device. It's important to know that the PETCT devices are mainly used for oncologic imaging or for cancer imaging –they are not cardiac optimized.
Our systems are cardiac optimized. Also the CT portion is associated with high radiation exposure. Additional costs for service contracts, additional real estate needed within the physician office. So we believe that the dedicated PET scanner is an ideal market entry to take advantage of the current market trends.
I don't believe that physicians will spend the additional capital for PET/CT nor is it necessary especially in today's tight health care environment.
UNIDENTIFIED PARTICIPANT: I have a question about the overall market – the molecular imaging market. How big is it from a broad view? Where do you see it growing over the next 10 years? And what is your current market share as a follow-up?
OLIVERIO: I can speak to that. I think we've already mentioned that there are 7,000 potential customers, not only for our PET device in addition to – for our radiopharmaceutical distribution device.
Seven million procedures currently performed annually, so as of right now there's only about 120,000 cardiac PET procedures done, so the amount of growth potential there is enormous, in addition to the 7 million SPECT procedures or 14 million injections that are performed. But from a market size standpoint I don't have that information right now.
ROONEY: From our standpoint we look to sell approximately 1,000 PET scanners over the next five years.
--------------------------------------------------------------------------------
UNIDENTIFIED PARTICIPANT: Just in terms of your revenue projections you said you're at $200 million now and expect to be up to $5 billion in so – I forget what time frame. How much is that going to be organic growth and how much is going to be dependent upon M&A or joint ventures?
ROONEY: Well, that's a good question. No, in fact over the next three years we're looking at $200 million and the next five years $1 billion in revenue. A majority of those numbers are from organic growth, yet our acceleration will be pretty significant in the next, next 18 months as we will know the extent of our certain strategic alliances and partners that we're working. These relationships will definitely assist us on a radiopharmaceutical side that advances us significantly.
Radiopharmaceuticals could really be a – will be a game changer and certain other radiopharmaceuticals that we're dealing with now could really expand that number even greater. I mean we're in this for the long haul, obviously – even longer than five years.
And we believe with our numbers we are going to have the largest market share – the largest market share in this market – with over 7,000 possibilities on the PET side. The pharma side we believe will have the largest market share of 10,000 opportunities. Anything else?
UNIDENTIFIED PARTICIPANT: One other quick question as it relates to partnerships and joint ventures, et cetera that you were discussing earlier. Is there anything that we should be looking for – to over the upcoming weeks or months in that regard or can you talk about that?
ROONEY: Yes, the next few weeks to a month or so we will have more information on certain alliances that we have. And we'll keep you posted. Thank you.
END
8K will be out this week. it will be a transcript of the May 5 conference. DO NOT expect any more details about the partnership. More than likely the NYSE company will release the news on the partnership first. I expect before the end of June we will have that info. probably sooner.
POSC should have put out the 8K when the stock was over .16 we could have jumped to .20